CY1111390T1 - Μεθοδος θεραπευτικης αγωγης καρκινου - Google Patents

Μεθοδος θεραπευτικης αγωγης καρκινου

Info

Publication number
CY1111390T1
CY1111390T1 CY20111100387T CY111100387T CY1111390T1 CY 1111390 T1 CY1111390 T1 CY 1111390T1 CY 20111100387 T CY20111100387 T CY 20111100387T CY 111100387 T CY111100387 T CY 111100387T CY 1111390 T1 CY1111390 T1 CY 1111390T1
Authority
CY
Cyprus
Prior art keywords
cancer
health education
cancer health
administration
relates
Prior art date
Application number
CY20111100387T
Other languages
English (en)
Inventor
Arundathy Nirmalini Pandite
Bonnie F Whitehead
Peter Tc Ho
Albert Benjamin Suttle
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of CY1111390T1 publication Critical patent/CY1111390T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Η παρούσα εφεύρεση αφορά μέθοδο θεραπευτικής αγωγής καρκίνου σε θηλαστικό με χορήγηση παραγώγων πυριμιδίνης. Πιο συγκεκριμένα, η μέθοδος αφορά μέθοδο θεραπευτικής αγωγής καρκίνου με χορήγηση 5-[[4-[(2,3-Διμεθυλ-2Η-ινδαζολ-6-υλ)μεθυλαμινο]-2-πυριμιδινυλ]αμινο]-2-μεθυλβενζολοσουλφοναμι-δίου ή άλατος ή διαλυτώματος αυτού.
CY20111100387T 2005-11-29 2011-04-18 Μεθοδος θεραπευτικης αγωγης καρκινου CY1111390T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74030805P 2005-11-29 2005-11-29
EP06838636A EP1954281B1 (en) 2005-11-29 2006-11-29 Cancer treatment method

Publications (1)

Publication Number Publication Date
CY1111390T1 true CY1111390T1 (el) 2015-08-05

Family

ID=37847172

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100387T CY1111390T1 (el) 2005-11-29 2011-04-18 Μεθοδος θεραπευτικης αγωγης καρκινου

Country Status (12)

Country Link
US (1) US20090005406A1 (el)
EP (2) EP2380572A1 (el)
JP (1) JP2009517397A (el)
AT (1) ATE500831T1 (el)
CY (1) CY1111390T1 (el)
DE (1) DE602006020611D1 (el)
DK (1) DK1954281T3 (el)
ES (1) ES2359517T3 (el)
HR (1) HRP20110244T1 (el)
PL (1) PL1954281T3 (el)
SI (1) SI1954281T1 (el)
WO (1) WO2007064753A2 (el)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2058307A1 (en) 2007-11-12 2009-05-13 Cellzome Ag Methods for the identification of JAK kinase interacting molecules and for the purification of JAK kinases
EP2490536A4 (en) * 2009-10-23 2013-04-17 Glaxo Wellcome Mfg Pte Ltd COMPOSITION AND METHOD
WO2011058179A1 (en) 2009-11-16 2011-05-19 Ratiopharm Gmbh 5- (4- (n- (2, 3 -dimethyl- 2h- indazol- 6 -yl) -n-methylamino) pyrimidin- 2 -ylamino) -2 -methylbenzenesulfonamide
WO2011069053A1 (en) 2009-12-04 2011-06-09 Teva Pharmaceutical Industries Ltd. Process for the preparation of pazopanip hcl and crystalline forms of pazopanib hcl
CA2814439A1 (en) 2010-10-27 2012-05-03 Novartis Ag Dosing regimes for the treatment of ocular vascular disease
AU2012332952B2 (en) 2011-10-31 2016-05-05 Novartis Ag Pazopanib formulation
EP2814493A4 (en) * 2012-02-17 2015-07-22 Pharmacyclics Inc COMBINATIONS OF HISTONE DEACETYLASE INHIBITOR AND PAZOPANIB, AND USES THEREOF
CN103319410B (zh) * 2012-03-22 2016-04-06 天津药物研究院 一种吲唑化合物的合成方法
CN103232443B (zh) * 2013-02-01 2014-12-10 天津药物研究院 一种吲唑衍生物的晶型及其制备和用途
US10730859B2 (en) * 2013-11-05 2020-08-04 Laurus Labs Limited Process for the preparation of pazopanib or a pharmaceutically acceptable salt thereof
CN110878089A (zh) * 2018-09-05 2020-03-13 江苏豪森药业集团有限公司 一种盐酸帕唑帕尼的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1343782T1 (sl) 2000-12-21 2009-10-31 Smithkline Beecham Corp Pirimidinamini kot modulatorji angiogeneze
JP4458746B2 (ja) 2001-01-16 2010-04-28 グラクソ グループ リミテッド 癌の治療方法
CA2489648A1 (en) 2002-06-17 2003-12-24 Smithkline Beecham Corporation Chemical process
EP1755394A4 (en) * 2004-04-16 2009-08-05 Smithkline Beecham Corp METHOD OF TREATING CANCER

Also Published As

Publication number Publication date
EP1954281B1 (en) 2011-03-09
EP2380572A1 (en) 2011-10-26
EP1954281A2 (en) 2008-08-13
DK1954281T3 (da) 2011-05-16
PL1954281T3 (pl) 2011-07-29
WO2007064753A3 (en) 2007-11-29
ATE500831T1 (de) 2011-03-15
WO2007064753A2 (en) 2007-06-07
SI1954281T1 (sl) 2011-06-30
JP2009517397A (ja) 2009-04-30
HRP20110244T1 (hr) 2011-04-30
US20090005406A1 (en) 2009-01-01
ES2359517T3 (es) 2011-05-24
DE602006020611D1 (de) 2011-04-21

Similar Documents

Publication Publication Date Title
CY1111390T1 (el) Μεθοδος θεραπευτικης αγωγης καρκινου
EA200970575A1 (ru) Соединения на основе 4-фенил-6-(2,2,2-трифтор-1-фенилэтокси)пиримидина и способы их применения
FIC20200014I1 (fi) Fostamatinibi tai fostamatinibin farmaseuttisesti hyväksyttävä suola tai fostamatinibin hydraatti, solvaatti, tai N-oksidi, tai fostamatinibin farmaseuttisesti hyväksyttävä suola, erityisesti fostamatinibi dinatrium, valinnaisesti hydraatin muodossa
NO20074431L (no) Pyrrolopyrimidiner nyttige som proteinkinaseinhibitorer
DK1968594T3 (da) Behandling af okulære neovaskulære lidelser, såsom makulær degeneration, striae angioides og makulært ødem
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
DE60314603D1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
DK1824856T3 (da) 2,4 (4,6)-pyrimidinderivater
PE20081800A1 (es) NUEVOS DERIVADOS DE 3-([1,2,4]TRIAZOLO[4,3-a]PIRIDIN-7-IL)BENZAMIDA
NZ594385A (en) Aminopyrimidines useful as kinase inhibitors
EA200800201A1 (ru) Кристаллические формы 4-метил-n-[3-(4-метилимидазол-1-ил)-5-трифторметилфенил]-3-(4-пиридин-3-илпиримидин-2-иламино)бензамида
EA200501333A1 (ru) 5,7-ДИАМИНОПИРАЗОЛО[4,3-d]ПИРИМИДИНЫ, ПОЛЕЗНЫЕ ПРИ ЛЕЧЕНИИ ГИПЕРТЕНЗИИ
EA201200669A1 (ru) ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
EA200800760A1 (ru) ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
ATE553106T1 (de) Heteroarylpyrrolopyridinone als kinaseinhibitoren
RS50807B (sr) 3,11 b-cis-dihidrotetrabenazin za lečenje šizofrenije i drugih psihoza
MY147790A (en) Stable emulsion composition
DE602005007181D1 (de) 1h-thieno 2,3-c-pyrazol-derivate als kinase-i-hemmer
DK1828151T3 (da) Malonamidderivater som inhibitorer af gamma-sekretase til behandlingen af alzheimer's sygdom
DE602005015319D1 (de) Prodrugs von als erk-proteinkinase-inhibitoren wirkenden pyrrolylpyrimidinen
DK1926729T3 (da) Benzothiazolcyclobutylaminderivater og deres anvendelse som histamin-3-receptorligander
EA200800324A1 (ru) Новый способ получения солей тиотропия
TW200639155A (en) Thiazolidinones, their production and use as pharmaceutical agents
NO20065791L (no) Asyklovir-formuleringer